Is it recommended for breastfeeding mothers to take cosentyx?

Is it safe to breastfeed while taking Cosentyx?
Clinical data on Cosentyx use during breastfeeding remain limited, but available evidence shows minimal transfer of secukinumab into breast milk. Most physicians consider the drug compatible with breastfeeding when the potential benefit to the mother outweighs any theoretical risk to the infant.

What do the prescribing guidelines say?
The Cosentyx prescribing information states that secukinumab may be present in human milk at low levels. It recommends weighing the benefits of breastfeeding against the mother's need for treatment and the possible risk to the breastfed child. No specific lactation contraindication appears on the label.

How long does the drug stay in the body?
Secukinumab has a half-life of roughly 22–31 days, so measurable levels can persist for several months after the last dose. This long clearance time means any decision to stop or start therapy during breastfeeding should account for prolonged systemic exposure.

What monitoring do doctors recommend for the baby?
Pediatricians typically advise watching the breastfed infant for signs of infection or reduced immune response, because Cosentyx blocks interleukin-17A and can modestly suppress immune activity. Routine growth and infection checks are often sufficient; additional laboratory testing is rarely required unless symptoms arise.

Are there any reported cases of problems in breastfed infants?
Published case reports and post-marketing surveillance have not identified clear adverse effects in infants exposed through breast milk. However, the total number of documented exposures is still small, so long-term outcomes are not fully established.

Can patients switch to an alternative treatment?
Some mothers explore other biologics or non-biologic options with shorter half-lives or more lactation safety data. Discussing these choices with both the prescribing rheumatologist or dermatologist and a lactation specialist helps tailor therapy to individual disease severity and infant safety needs.